Citizens Jmp Issues Positive Forecast for argenex (NASDAQ:ARGX) Stock Price

by · The Markets Daily

argenex (NASDAQ:ARGX – Free Report) had its price target hoisted by Citizens Jmp from $925.00 to $944.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has a market outperform rating on the stock.

Several other brokerages have also commented on ARGX. Wolfe Research restated a “peer perform” rating on shares of argenex in a research report on Monday, November 24th. Royal Bank Of Canada boosted their target price on argenex from $860.00 to $925.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. HC Wainwright raised their price target on shares of argenex from $915.00 to $940.00 and gave the company a “buy” rating in a report on Friday. JPMorgan Chase & Co. boosted their price target on argenex from $925.00 to $1,100.00 and gave the company an “overweight” rating in a report on Monday, December 8th. Finally, Evercore boosted their target price on shares of argenex from $775.00 to $910.00 and gave the stock an “outperform” rating in a report on Friday, October 31st. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, argenex has an average rating of “Moderate Buy” and an average price target of $999.22.

Check Out Our Latest Analysis on ARGX

argenex Stock Performance

Shares of argenex stock traded down $4.61 during trading on Friday, reaching $766.92. 464,736 shares of the company’s stock were exchanged, compared to its average volume of 347,294. The company has a market cap of $47.46 billion, a P/E ratio of 39.29, a PEG ratio of 0.67 and a beta of 0.37. argenex has a 1-year low of $510.05 and a 1-year high of $934.62. The firm’s 50-day moving average price is $826.36 and its 200 day moving average price is $810.76.

argenex (NASDAQ:ARGX – Get Free Report) last posted its earnings results on Thursday, February 26th. The company reported $8.02 EPS for the quarter, beating the consensus estimate of $6.05 by $1.97. argenex had a return on equity of 63.59% and a net margin of 30.42%.The firm had revenue of $1.32 billion during the quarter, compared to the consensus estimate of $1.30 billion. As a group, equities research analysts predict that argenex will post 3.13 EPS for the current year.

Hedge Funds Weigh In On argenex

Institutional investors and hedge funds have recently made changes to their positions in the stock. Abound Wealth Management lifted its stake in argenex by 3,200.0% in the fourth quarter. Abound Wealth Management now owns 33 shares of the company’s stock valued at $28,000 after buying an additional 32 shares during the last quarter. Sound Income Strategies LLC acquired a new stake in argenex in the 4th quarter worth about $28,000. Ameriflex Group Inc. purchased a new stake in shares of argenex during the 3rd quarter valued at $32,000. Aventura Private Wealth LLC purchased a new stake in argenex during the fourth quarter worth approximately $38,000. Finally, Sunbelt Securities Inc. purchased a new stake in shares of argenex during the third quarter valued at approximately $36,000. 60.32% of the stock is owned by institutional investors and hedge funds.

More argenex News

Here are the key news stories impacting argenex this week:

  • Positive Sentiment: Positive Phase‑3 topline results for VYVGART in ocular myasthenia gravis (ADAPT OCULUS); study met its primary endpoint and argenx plans a supplemental BLA submission to expand the label into oMG, which materially expands commercial opportunity. argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial
  • Positive Sentiment: Strong quarterly and full‑year commercial performance: $1.3B in Q4 product net sales and $4.2B for FY2025 (≈90% YoY growth), reinforcing revenue momentum and the company’s commercialization traction. argenx Reports Full Year 2025 Financial Results
  • Positive Sentiment: Q4 beat on the numbers: $8.02 EPS vs. $6.05 consensus and $1.32B revenue vs. $1.30B consensus, with healthy margins and ROE — data that supports higher earnings expectations. MarketBeat Q4 Earnings Summary
  • Positive Sentiment: Certain sell‑side firms raised targets after the results (Citizens JMP and HC Wainwright among them), signaling continued analyst conviction in upside from commercialization and label expansion. These Analysts Revise Their Forecasts On Argenx After Q4 Earnings
  • Neutral Sentiment: Other major firms trimmed price targets (Wells Fargo, Guggenheim, RBC) but generally maintained positive ratings (overweight/outperform/buy). These adjustments temper upside expectations but keep buy convictions intact. These Analysts Revise Their Forecasts On Argenx After Q4 Earnings
  • Neutral Sentiment: Reports flag a “large increase” in short interest for February, but the published short‑interest numbers appear inconsistent/erroneous (zeros/NaN). As reported data is unreliable, the market impact is unclear.

argenex Company Profile

(Get Free Report)

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.

Recommended Stories